Prefrontal cortex iron content in neurodegeneration and healthy subjects: A systematic review

Abstract

Iron accumulation in the prefrontal cortex (PFC) has been implicated in neurodegeneration and cognitive decline. Magnetic resonance imaging (MRI) enables noninvasive quantification of brain iron content and deposition. This review aimed to summarize the evidence on the MRI-based assessment of PFC iron accumulation in healthy individuals and patients with neurodegeneration. A systematic preliminary literature review was conducted using the PubMed, Scopus, Web of Science, and Embase databases. MRI techniques for capturing susceptibility changes reflecting iron, such as susceptibility-weighted imaging (SWI), quantitative susceptibility mapping (QSM), and R2* mapping, were included. Data were extracted, and narrative synthesis was performed. Twelve studies that measured PFC iron levels using MRI in diseases with neurodegeneration (five studies) and healthy subjects (seven studies) were included. In general, studies involving diseases with neurodegeneration have found that increased PFC iron content correlates with cognitive impairment. Aging studies on healthy subjects have reported that age-related accumulation of PFC iron, particularly in the dorsolateral, medial, and anterior subregions, increases with age, and is associated with reduced dopamine signaling and poorer cognition. MRI techniques, such as QSM, can quantify prefrontal iron accumulation in diseases with neurodegeneration and aging. As imaging biomarkers, increased prefrontal iron levels may contribute to neurodegeneration and cognitive decline. Longitudinal studies combining advanced QSM and other advanced neuroimaging techniques with cognitive assessments may further elucidate the effects of iron dysregulation on PFC function. Thus, our findings highlight the importance of MRI as a sensitive tool for assessing PFC iron content and its potential role in understanding the pathogenesis of neurodegeneration and the effects of aging on the brain.

Keywords

cognitive aging / iron / magnetic resonance imaging / neurodegeneration / prefrontal cortex / quantitative susceptibility mapping

References

[1] Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958; 3(1): 41-51.

[2] Galaris D, Barbouti A, Pantopoulos K. Iron homeostasis and oxidative stress: An intimate relationship. Biochim Biophys Acta (BBA) - Mol Cell Res. 2019; 1866(12):118535.

[3] Chifman J, Laubenbacher R, Torti SV. A systems biology approach to iron metabolism. Adv Exp Med Biol. 2014; 844: 201-225.

[4] McCann S, Perapoch Amadó M, Moore SE. The role of iron in brain development: A systematic review. Nutrients. 2020; 12(7):2001.

[5] Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet. Neurol. 2014; 13(10): 1045-1060.

[6] Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. GLIA. 2009; 57(5): 467-478.

[7] Ferreira A, Neves P, Gozzelino R. Multilevel impacts of iron In the brain: the cross talk between neurophysiological mechanisms, cognition, and social behavior. Pharmaceuticals. 2019; 12(3):126.

[8] Hare D, Ayton S, Bush A, Lei P. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci. 2013; 5: 34. https://www.frontiersin.org/articles/10.3389/fnagi.2013.00034

[9] Beard J. Iron deficiency alters brain development and functioning. J Nutr. 2003; 133(5): 1468.

[10] Rosenblum SL, Kosman DJ. Aberrant cerebral iron trafficking co-morbid with chronic inflammation: molecular mechanisms and pharmacologic intervention. Front Neurol. 2022; 13:855751.

[11] Ndayisaba A, Kaindlstorfer C, Wenning GK. Iron in neurodegeneration – cause or consequence? Front Neurosci. 2019; 13:180.

[12] Acosta-Cabronero J, Machts J, Schreiber S, et al. Quantitative susceptibility MRI to detect brain iron In amyotrophic lateral sclerosis. Radiology. 2018; 289(1): 195-203.

[13] Bhattarai A, Egan GF, Talman P, Chua P, Chen Z. Magnetic resonance iron imaging in amyotrophic lateral sclerosis. J Magn Reson Imaging. 2022; 55(5): 1283-1300.

[14] Smith MA, Zhu X, Tabaton M, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimer's Dis. 2010; 19(1): 363-372.

[15] Tu J, Yan J, Liu J, Liu D, Wang X, Gao F. Iron deposition in the precuneus is correlated with mild cognitive impairment in patients with cerebral microbleeds: A quantitative susceptibility mapping study. Front Neurosci. 2022; 16:944709.

[16] Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, Nestor PJ. In vivo MRI mapping of brain iron deposition across the adult lifespan. J Neurosci. 2016; 36(2): 364-374.

[17] Rodrigue KM, Haacke EM, Raz N. Differential effects of age and history of hypertension on regional brain volumes and iron. Neuroimage. 2011; 54(2): 750-759.

[18] Ogg RJ, Langston JW, Haacke EM, Steen RG, Taylor JS. The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging. 1999; 17(8): 1141-1148.

[19] Jobson DD, Hase Y, Clarkson AN, Kalaria RN. The role of the medial prefrontal cortex in cognition, ageing and dementia. Brain Commun. 2021; 3(3):fcab125.

[20] Lotan A, Luza S, Opazo CM, et al. Perturbed iron biology in the prefrontal cortex of people with schizophrenia. Mol Psychiatry. 2023; 28: 1-13.

[21] Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology. 2022; 47(1): 72-89.

[22] Funahashi S. Working memory in the prefrontal cortex. Brain Sci. 2017; 7(5):49.

[23] Dusek P, Hofer T, Alexander J, Roos PM, Aaseth JO. Cerebral iron deposition in neurodegeneration. Biomolecules. 2022; 12(5):714.

[24] Abbasi U, Abbina S, Gill A, Takuechi LE, Kizhakkedathu JN. Role of iron in the molecular pathogenesis of diseases and therapeutic opportunities. ACS Chem Biol. 2021; 16(6): 945-972.

[25] Kotze MJ, van Velden DP, van Rensburg SJ, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: new insights for clinical application. EJIFCC. 2009; 20(2): 108-123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975278/

[26] Mohammadi S, Ghaderi S, Mohammadi H, Fatehi F. Simultaneous increase of mean susceptibility and mean kurtosis in the substantia nigra as an MRI neuroimaging biomarker for early-stage Parkinson's disease: a systematic review and meta-analysis. J Magn Reson Imaging. 2024; 61: 1797-1809.

[27] Madden DJ, Merenstein JL. Quantitative susceptibility mapping of brain iron in healthy aging and cognition. Neuroimage. 2023; 282:120401.

[28] He C, Guan X, Zhang W, et al. Quantitative susceptibility Atlas construction in Montreal neurological institute space: towards histological-consistent iron-rich deep brain nucleus subregion identification. Brain Structure and Function. 2023; 228(5): 1045-1067.

[29] Wang F, Zhang M, Li Y, et al. Alterations in brain iron deposition with progression of late-life depression measured by magnetic resonance imaging (MRI)-based quantitative susceptibility mapping. Quant Imaging Med Surg. 2022; 12(7): 3873-3888.

[30] Mohammadi S, Ghaderi S. Parkinson's disease and Parkinsonism syndromes: evaluating iron deposition in the putamen using magnetic susceptibility MRI techniques - a systematic review and literature analysis. Heliyon. 2024; 10(7):e27950.

[31] Li W, Wu B, Liu C. Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage. 2011; 55(4): 1645-1656.

[32] Halefoglu AM, Yousem DM. Susceptibility weighted imaging: clinical applications and future directions. World J Radiol. 2018; 10(4): 30-45.

[33] Heath F, Hurley SA, Johansen-Berg H, Sampaio-Baptista C. Advances in noninvasive myelin imaging. Dev Neurobiol. 2018; 78(2): 136-151.

[34] Granziera C, Wuerfel J, Barkhof F, et al. Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain. 2021; 144(5): 1296-1311.

[35] Liu C, Li W, Tong KA, Yeom KW, Kuzminski S. Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 2015; 42(1): 23-41.

[36] Yoo S, Kim J, Schenck JF, Lee SK. Magnetic susceptibility imaging of human habenula at 3 T. Sci Rep. 2020; 10(1):19357.

[37] Ravanfar P, Loi SM, Syeda WT, et al. Systematic review: quantitative susceptibility mapping (QSM) of brain iron profile in neurodegenerative diseases. Front Neurosci. 2021; 15:618435.

[38] Treit S, Naji N, Seres P, et al. R2* and quantitative susceptibility mapping in deep gray matter of 498 healthy controls from 5 to 90 years. Hum Brain Mapp. 2021; 42(14): 4597-4610.

[39] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.

[40] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa ScaleScale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. https://cir.nii.ac.jp/crid/1573950401149188096

[41] Herzog R, Álvarez-Pasquin J, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013; 13(1):154.

[42] Parasuaraman G, Ayyasamy L, Aune D, et al. The association between body mass index, abdominal fatness, and weight change and the risk of adult asthma: a systematic review and meta-analysis of cohort studies. Sci Rep. 2023; 13(1): 7745.

[43] Gelman N, Gorell JM, Barker PB, et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology. 1999; 210(3): 759-767.

[44] Burger A, Kotze MJ, Stein DJ, Janse van Rensburg S, Howells FM. The relationship between measurement of in vivo brain glutamate and markers of iron metabolism: A proton magnetic resonance spectroscopy study in healthy adults. Eur J Neurosci. 2020; 51(4): 984-990.

[45] Griffanti L, Klein JC, Szewczyk-Krolikowski K, et al. Cohort profile: the Oxford Parkinson's Disease Centre Discovery Cohort MRI substudy (OPDC-MRI). BMJ Open. 2020; 10(8):034110.

[46] Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson's disease. J Neurol, Neurosurg Psychiatry. 2020; 91(4): 418-425.

[47] Chen K, Zhang L, Mao H, et al. The impact of iron deposition on the fear circuit of the brain in patients with Parkinson's disease and anxiety. Front Aging Neurosci. 2023; 15:1116516.

[48] van Bergen JMG, Li X, Hua J, et al. Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci Rep. 2016; 6:35514.

[49] Pontillo G, Petracca M, Monti S, et al. Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin. Eur Radiol. 2023; 33(3): 2185-2194.

[50] Lorio S, Lutti A, Kherif F, et al. Disentangling in vivo the effects of iron content and atrophy on the ageing human brain. Neuroimage. 2014; 103: 280-289.

[51] Allen M, Glen JC, Müllensiefen D, et al. Metacognitive ability correlates with hippocampal and prefrontal microstructure. Neuroimage. 2017; 149: 415-423.

[52] Burgetova R, Dusek P, Burgetova A, et al. Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. Quant Imaging Med Surg. 2021; 11(9): 3906-3919.

[53] Gustavsson J, Johansson J, Falahati F, et al. The iron-dopamine d1 coupling modulates neural signatures of working memory across adult lifespan. Neuroimage. 2023; 279:120323.

[54] Zachariou V, Pappas C, Bauer CE, Seago ER, Gold BT. Exploring the links among brain iron accumulation, cognitive performance, and dietary intake in older adults: a longitudinal MRI study. Neurobiol Aging. 2025; 145: 1-12.

[55] Ghaderi S, Mohammadi S, Nezhad NJ, Karami S, Sayehmiri F. Iron quantification in basal ganglia: quantitative susceptibility mapping as a potential biomarker for Alzheimer's disease - a systematic review and meta-analysis. Front Neurosci. 2024; 18:1338891.

[56] Lara AH, Wallis JD. The role of prefrontal cortex in working memory: a mini review. Front Syst Neurosci. 2015; 9:173.

[57] Weingarten CP, Sundman MH, Hickey P, Chen N. Neuroimaging of Parkinson's disease: expanding views. Neurosci Biobehav Rev. 2015; 59: 16-52.

[58] Girotti M, Adler SM, Bulin SE, Fucich EA, Paredes D, Morilak DA. Prefrontal cortex executive processes affected by stress in health and disease. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 85: 161-179.

[59] Nieuwhof F, Reelick MF, Maidan I, et al. Measuring prefrontal cortical activity during dual task walking in patients with Parkinson's disease: feasibility of using a new portable fNIRS device. Pilot Feasibility Stud. 2016; 2(1): 59.

[60] Monti JM, Moulton CJ, Cohen NJ. The role of nutrition on cognition and brain health in ageing: a targeted approach. Nutr Res Rev. 2015; 28(2): 167-180.

[61] Gustavsson J, Papenberg G, Falahati F, Laukka EJ, Kalpouzos G. Contributions of the Catechol-O-Methyltransferase Val158Met polymorphism to changes In brain iron across adulthood and their relationships to working memory. Front Hum Neurosci. 2022; 16:838228. https://www.frontiersin.org/articles/10.3389/fnhum.2022.838228

[62] Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol. 2017; 155: 96-119.

[63] Bäckman L, Farde L. Role of dopamine systems in cognitive aging. In: Cabeza R, Nyberg L, Park D, eds., Cognitive Neuroscience of Aging: Linking Cognitive and Cerebral Aging. Oxford University Press; 2004.

[64] Rodrigue KM, Daugherty AM, Haacke EM, Raz N. The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cerebral Cortex. 2013; 23(7): 1533-1541.

[65] Biel D, Steiger TK, Bunzeck N. Age-related iron accumulation and demyelination in the basal ganglia are closely related to verbal memory and executive functioning. Sci Rep. 2021; 11: 9438.

[66] Uchida Y, Kan H, Sakurai K, Oishi K, Matsukawa N. Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: the expectations and limitations. Front Neurosci. 2022; 16:938092.

[67] Fu X, Deng W, Cui X, et al. Time-Specific pattern of iron deposition in different regions in Parkinson's disease measured by quantitative susceptibility mapping. Front Neurol. 2021; 12:631210.

[68] Levi S, Ripamonti M, Moro AS, Cozzi A. Iron imbalance in neurodegeneration. Mol Psychiatry. 2024; 29: 1-14.

[69] Li Z, Feng R, Liu Q, et al. APART-QSM: an improved sub-voxel quantitative susceptibility mapping for susceptibility source separation using an iterative data fitting method. Neuroimage. 2023; 274:120148.

[70] Chen J, Gong NJ, Chaim KT, Otaduy MCG, Liu C. Decompose quantitative susceptibility mapping (QSM) to sub-voxel diamagnetic and paramagnetic components based on gradient-echo MRI data. Neuroimage. 2021; 242:118477.

[71] Foster CM, Kennedy KM, Daugherty AM, Rodrigue KM. Contribution of iron and Aβ to age differences in entorhinal and hippocampal subfield volume. Neurology. 2020; 95(18): e2586-e2594.

[72] Bilgic B, Costagli M, Chan KS, et al. Recommended implementation of quantitative susceptibility mapping for clinical research in the brain: a consensus of the ISMRM electro-magnetic tissue properties study group. Magn Reson Med. 2024; 91(5): 1834-1862.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.